This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
by Zacks Equity Research
THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
by Zacks Equity Research
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
Tenet (THC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Tenet (THC) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tenet Healthcare (THC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of +41.55% and +2.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights HCA Healthcare, Tenet Healthcare, Universal Health and Community Health Systems
by Zacks Equity Research
Despite industry pressures, HCA, THC, UHS, and CYH are leveraging M&A, tech, and rising demand to drive resilient growth.
HCA Healthcare to Report Q2 Earnings: Key Estimates to Note
by Zacks Equity Research
The Zacks Consensus Estimate for HCA's Q2 EPS and revenues suggests a year-over-year upside despite higher costs and surgery volume pressure.
Hospital Market May Be Sick, But These 4 Stocks Are Healthy
by Kaibalya Pravo Dey
HCA, THC, UHS, and CYH are showing strength through smart expansions and solid earnings despite hospital industry headwinds.
HCA Healthcare (HCA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
HCA (HCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tenet Healthcare (THC) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Tenet Healthcare (THC) concluded the recent trading session at $175.14, signifying a +1.01% move from its prior day's close.
Insights Into Tenet (THC) Q2: Wall Street Projections for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Tenet (THC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Tenet Healthcare Corporation (THC) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Tenet Healthcare (THC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tenet Healthcare (THC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
The latest trading day saw Tenet Healthcare (THC) settling at $173.66, representing a +1.32% change from its previous close.
Is Tenet (THC) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Tenet (THC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the most recent trading session, Tenet Healthcare (THC) closed at $172.22, indicating a -2.94% shift from the previous trading day.
Will Tenet (THC) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Tenet (THC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tenet Healthcare (THC) Stock Moves -1.46%: What You Should Know
by Zacks Equity Research
In the latest trading session, Tenet Healthcare (THC) closed at $169.01, marking a -1.46% move from the previous day.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tenet Healthcare (THC) Rises Higher Than Market: Key Facts
by Zacks Equity Research
The latest trading day saw Tenet Healthcare (THC) settling at $171.52, representing a +1.42% change from its previous close.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Brokers Suggest Investing in Tenet (THC): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Tenet (THC) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?